Your browser doesn't support javascript.
loading
Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer.
Merz, Valeria; Zecchetto, Camilla; Santoro, Raffaela; Simionato, Francesca; Sabbadini, Fabio; Mangiameli, Domenico; Piro, Geny; Cavaliere, Alessandro; Deiana, Michela; Valenti, Maria Teresa; Bazan, Diana; Fedele, Vita; Lonardi, Sara; Melisi, Davide.
Afiliação
  • Merz V; Digestive Molecular Clinical Oncology Research Unit, Section of Medical Oncology, Department of Medicine, University of Verona, Verona, Italy.
  • Zecchetto C; Digestive Molecular Clinical Oncology Research Unit, Section of Medical Oncology, Department of Medicine, University of Verona, Verona, Italy.
  • Santoro R; Digestive Molecular Clinical Oncology Research Unit, Section of Medical Oncology, Department of Medicine, University of Verona, Verona, Italy.
  • Simionato F; Digestive Molecular Clinical Oncology Research Unit, Section of Medical Oncology, Department of Medicine, University of Verona, Verona, Italy.
  • Sabbadini F; Digestive Molecular Clinical Oncology Research Unit, Section of Medical Oncology, Department of Medicine, University of Verona, Verona, Italy.
  • Mangiameli D; Digestive Molecular Clinical Oncology Research Unit, Section of Medical Oncology, Department of Medicine, University of Verona, Verona, Italy.
  • Piro G; Digestive Molecular Clinical Oncology Research Unit, Section of Medical Oncology, Department of Medicine, University of Verona, Verona, Italy.
  • Cavaliere A; Digestive Molecular Clinical Oncology Research Unit, Section of Medical Oncology, Department of Medicine, University of Verona, Verona, Italy.
  • Deiana M; Section of Internal Medicine D, Department of Medicine, University of Verona, Verona, Italy.
  • Valenti MT; Section of Internal Medicine D, Department of Medicine, University of Verona, Verona, Italy.
  • Bazan D; Section of Neurology, Department of Neurological, Psychological, Morphological and Motor Sciences, University of Verona, Verona, Italy.
  • Fedele V; Digestive Molecular Clinical Oncology Research Unit, Section of Medical Oncology, Department of Medicine, University of Verona, Verona, Italy.
  • Lonardi S; Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
  • Melisi D; Digestive Molecular Clinical Oncology Research Unit, Section of Medical Oncology, Department of Medicine, University of Verona, Verona, Italy. davide.melisi@univr.it.
Clin Cancer Res ; 26(17): 4661-4669, 2020 09 01.
Article em En | MEDLINE | ID: mdl-32532788
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Protocolos de Quimioterapia Combinada Antineoplásica / Interleucina-8 / Resistencia a Medicamentos Antineoplásicos / MAP Quinase Quinase Quinases Tipo de estudo: Observational_studies / Prognostic_studies Limite: Adult / Aged / Aged80 / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Itália
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Protocolos de Quimioterapia Combinada Antineoplásica / Interleucina-8 / Resistencia a Medicamentos Antineoplásicos / MAP Quinase Quinase Quinases Tipo de estudo: Observational_studies / Prognostic_studies Limite: Adult / Aged / Aged80 / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Itália